Advantages of Polymyxin B + Ceftazidime-Avibactam + Aztreonam Combination
The triple combination of polymyxin B, ceftazidime-avibactam, and aztreonam provides superior mortality reduction and bacterial eradication against metallo-β-lactamase-producing carbapenem-resistant Enterobacterales (CRE) compared to other antimicrobial regimens, with the most compelling evidence showing 30-day mortality reduction from 44% to 19.2% in bloodstream infections. 1
Primary Clinical Benefits
Mortality and Treatment Failure Reduction
For metallo-β-lactamase-producing CRE bloodstream infections, ceftazidime-avibactam plus aztreonam reduces 30-day mortality by 63% (HR: 0.37,95% CI 0.13-0.74) compared to other active antimicrobial agents. 1
Clinical treatment failure rates decrease by 70% (HR: 0.30,95% CI 0.14-0.65) when using this combination. 1
Hospital length of stay is reduced by 51% (HR: 0.49,95% CI -0.82) with ceftazidime-avibactam plus aztreonam therapy. 1
In critical cases (71.9% critically ill patients), the curative rate reaches 77.5% for NDM- or NDM+OXA-48-positive CRE infections when polymyxin is added to the ceftazidime-avibactam/aztreonam base. 1
Mechanistic Synergy Against Resistant Pathogens
The combination exploits complementary mechanisms of action:
Aztreonam is not hydrolyzed by metallo-β-lactamases (NDM, VIM, IMP), maintaining activity against these enzymes. 1
Ceftazidime-avibactam provides synergistic activity by protecting aztreonam from degradation and covering serine β-lactamases (KPC, OXA-48). 1
Polymyxin B disrupts the outer membrane, enhancing β-lactam penetration and killing persister cells that survive β-lactam exposure alone. 2
Time-lapse microscopy demonstrates polymyxin B creates spheroplasts while aztreonam and ceftazidime induce long filamentous cells through PBP3 binding, providing mechanistically distinct killing pathways. 2
Resistance Suppression
This triple combination prevents emergence of resistant subpopulations:
Polymyxin B combined with ceftazidime-avibactam suppresses regrowth of polymyxin-heteroresistant subpopulations that would otherwise amplify during monotherapy. 3
In hollow fiber infection models against MBL-producing K. pneumoniae, high-dose polymyxin B added to aztreonam/ceftazidime-avibactam achieves sustained bacterial clearance through 216 hours, whereas lower doses permit regrowth to ~9 log10 CFU/mL. 2
The combination prevents selection of aztreonam-resistant mutants that commonly emerge during aztreonam monotherapy against Pseudomonas aeruginosa. 4
Specific Pathogen Coverage
Metallo-β-Lactamase-Producing Enterobacterales
Ceftazidime-avibactam plus aztreonam is the preferred regimen for severe infections caused by metallo-β-lactamase-producing CRE according to 2023 guidelines (weak recommendation, very low-quality evidence). 1
Against NDM-producing K. pneumoniae, 62.5% of isolates shift from resistant to susceptible when tested with the ceftazidime-avibactam/aztreonam combination. 5
The combination demonstrates potent in vitro activity against CRE expressing multiple β-lactamases across Ambler classes A, B, C, and D. 6
MBL-Producing Pseudomonas aeruginosa
Among 64 carbapenemase-producing P. aeruginosa isolates (61 VIM, 2 NDM, 1 OXA), the ceftazidime-avibactam/aztreonam combination successfully lowers MIC values compared to carbapenemase-negative controls. 7
Clinical success and cure were achieved in 7 of 8 patients with VIM-producing P. aeruginosa infections treated with this combination, with no infection relapses documented. 4
NDM-Producing Acinetobacter baumannii
Against NDM-1-producing A. baumannii (MIC aztreonam >64 mg/L, MIC ceftazidime-avibactam >128/4 mg/L), adding low-dose polymyxin B to aztreonam/ceftazidime-avibactam enables achievement of target aztreonam IC50 values ≥96% of dosing time. 8
Monte Carlo simulations demonstrate standard aztreonam dosing combined with ceftazidime-avibactam and polymyxin B maintains therapeutic concentrations against NDM-producing CRAB. 8
Optimal Dosing Strategy
When polymyxin B is added to the ceftazidime-avibactam/aztreonam base:
High-dose polymyxin B (not specifically defined in guidelines but implied >2 mg/L based on research) provides long-term bacterial clearance. 2
Low-dose polymyxin B (0.5-2 mg/L) combined with clinically achievable ceftazidime-avibactam concentrations (0.5-1× MIC) results in sustained killing against polymyxin-heteroresistant isolates. 3
Polymyxin B should be used judiciously in patients with renal insufficiency. 1
Critical Implementation Considerations
Carbapenemase typing should be ascertained before initiating therapy whenever possible to guide optimal combination selection. 1
Common Pitfalls to Avoid
Do not use ceftazidime-avibactam or aztreonam monotherapy against metallo-β-lactamase producers—both agents are required for synergy. 1
Avoid polymyxin monotherapy against heteroresistant strains, as resistant subpopulations will amplify during treatment. 3
Do not assume all CRE are metallo-β-lactamase producers—KPC and OXA-48 producers may not require aztreonam addition. 1
Evidence Quality Caveat
All guideline recommendations carry very low-quality evidence, reflecting observational study designs and small sample sizes. 1 The observed mortality benefits may change with future randomized controlled trials, but the magnitude of effect (>50% mortality reduction) and mechanistic rationale support use in severe infections where alternatives are limited.